The Columbia, MD-based regenerative medicine company develops products used in acute care settings to treat and manage moderate-to-severe wounds and reinforcement of soft tissue surgical defects. Top seller is MicroMatrix, accounting for over 46% of 2019 revenue, a urinary bladder matrix used for acute and chronic wounds.
2019 Financials: Revenue: $100.8M (+13%); Operating Expenses: $80.3M (+6%); Net Income: $1.4M (+145%); Cash Flow Ops: $0.6M (+123%).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.